Pfizer’s $4.9bn bet on obesity startup Metsera is looking promising, with 14.1% weight loss reported in a Phase IIb trial. In the VESPER-1 trial (NCT06712836), MET-097i, a glucagon-like peptide-1 ...
Gambling content 21+. The New York Post may receive an affiliate commission if you sign up through our links. Read our editorial standards for more information. The 2025-26 Premier League could take a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback